id	sid	tid	token	lemma	pos
dpc-1105	1	1	dermatology	dermatology	NOUN
dpc-1105	1	2	:	:	PUNCT
dpc-1105	1	3	practical	practical	ADJ
dpc-1105	1	4	and	and	CCONJ
dpc-1105	1	5	conceptual	conceptual	ADJ
dpc-1105	1	6	letter	letter	NOUN
dpc-1105	2	1	|	|	ADV
dpc-1105	2	2	dermatol	dermatol	ADJ
dpc-1105	2	3	pract	pract	NOUN
dpc-1105	2	4	concept	concept	NOUN
dpc-1105	2	5	2020;10(4):2020102	2020;10(4):2020102	NUM
dpc-1105	2	6	1	1	NUM
dpc-1105	2	7	dermatology	dermatology	NOUN
dpc-1105	2	8	practical	practical	ADJ
dpc-1105	2	9	&	&	CCONJ
dpc-1105	2	10	conceptual	conceptual	ADJ
dpc-1105	2	11	introduction	introduction	NOUN
dpc-1105	2	12	several	several	ADJ
dpc-1105	2	13	guidelines	guideline	NOUN
dpc-1105	2	14	recommend	recommend	VERB
dpc-1105	2	15	phototherapy	phototherapy	NOUN
dpc-1105	2	16	,	,	PUNCT
dpc-1105	2	17	systemic	systemic	ADJ
dpc-1105	2	18	agents	agent	NOUN
dpc-1105	2	19	,	,	PUNCT
dpc-1105	2	20	or	or	CCONJ
dpc-1105	2	21	biologic	biologic	NOUN
dpc-1105	2	22	therapy	therapy	NOUN
dpc-1105	2	23	for	for	ADP
dpc-1105	2	24	the	the	DET
dpc-1105	2	25	treatment	treatment	NOUN
dpc-1105	2	26	of	of	ADP
dpc-1105	2	27	moderate	moderate	ADJ
dpc-1105	2	28	-	-	PUNCT
dpc-1105	2	29	to	to	ADP
dpc-1105	2	30	-	-	PUNCT
dpc-1105	2	31	severe	severe	ADJ
dpc-1105	2	32	psoriasis	psoriasis	NOUN
dpc-1105	2	33	.	.	PUNCT
dpc-1105	3	1	sequential	sequential	ADJ
dpc-1105	3	2	use	use	NOUN
dpc-1105	3	3	of	of	ADP
dpc-1105	3	4	more	more	ADJ
dpc-1105	3	5	than	than	ADP
dpc-1105	3	6	1	1	NUM
dpc-1105	3	7	biologic	biologic	NOUN
dpc-1105	3	8	has	have	AUX
dpc-1105	3	9	become	become	VERB
dpc-1105	3	10	more	more	ADV
dpc-1105	3	11	common	common	ADJ
dpc-1105	3	12	due	due	ADJ
dpc-1105	3	13	to	to	ADP
dpc-1105	3	14	primary	primary	ADJ
dpc-1105	3	15	or	or	CCONJ
dpc-1105	3	16	secondary	secondary	ADJ
dpc-1105	3	17	failure	failure	NOUN
dpc-1105	3	18	with	with	ADP
dpc-1105	3	19	this	this	DET
dpc-1105	3	20	type	type	NOUN
dpc-1105	3	21	of	of	ADP
dpc-1105	3	22	treatment	treatment	NOUN
dpc-1105	3	23	and	and	CCONJ
dpc-1105	3	24	an	an	DET
dpc-1105	3	25	increase	increase	NOUN
dpc-1105	3	26	in	in	ADP
dpc-1105	3	27	the	the	DET
dpc-1105	3	28	number	number	NOUN
dpc-1105	3	29	of	of	ADP
dpc-1105	3	30	drugs	drug	NOUN
dpc-1105	3	31	available	available	ADJ
dpc-1105	3	32	.	.	PUNCT
dpc-1105	4	1	however	however	ADV
dpc-1105	4	2	,	,	PUNCT
dpc-1105	4	3	the	the	DET
dpc-1105	4	4	order	order	NOUN
dpc-1105	4	5	of	of	ADP
dpc-1105	4	6	usage	usage	NOUN
dpc-1105	4	7	of	of	ADP
dpc-1105	4	8	these	these	DET
dpc-1105	4	9	drugs	drug	NOUN
dpc-1105	4	10	is	be	AUX
dpc-1105	4	11	still	still	ADV
dpc-1105	4	12	speculative	speculative	ADJ
dpc-1105	4	13	.	.	PUNCT
dpc-1105	5	1	we	we	PRON
dpc-1105	5	2	report	report	VERB
dpc-1105	5	3	about	about	ADP
dpc-1105	5	4	a	a	DET
dpc-1105	5	5	patient	patient	NOUN
dpc-1105	5	6	with	with	ADP
dpc-1105	5	7	severe	severe	ADJ
dpc-1105	5	8	psoriasis	psoriasis	NOUN
dpc-1105	5	9	with	with	ADP
dpc-1105	5	10	primary	primary	ADJ
dpc-1105	5	11	failure	failure	NOUN
dpc-1105	5	12	to	to	PART
dpc-1105	5	13	respond	respond	VERB
dpc-1105	5	14	after	after	ADP
dpc-1105	5	15	treatment	treatment	NOUN
dpc-1105	5	16	with	with	ADP
dpc-1105	5	17	ustekinumab	ustekinumab	NOUN
dpc-1105	5	18	and	and	CCONJ
dpc-1105	5	19	adalimumab	adalimumab	NOUN
dpc-1105	5	20	who	who	PRON
dpc-1105	5	21	achieved	achieve	VERB
dpc-1105	5	22	psoriasis	psoriasis	NOUN
dpc-1105	5	23	area	area	NOUN
dpc-1105	5	24	and	and	CCONJ
dpc-1105	5	25	severity	severity	NOUN
dpc-1105	5	26	index	index	NOUN
dpc-1105	5	27	(	(	PUNCT
dpc-1105	5	28	pasi	pasi	NOUN
dpc-1105	5	29	)	)	PUNCT
dpc-1105	5	30	100	100	NUM
dpc-1105	5	31	score	score	NOUN
dpc-1105	5	32	with	with	ADP
dpc-1105	5	33	secukinumab	secukinumab	NOUN
dpc-1105	5	34	in	in	ADP
dpc-1105	5	35	8	8	NUM
dpc-1105	5	36	weeks	week	NOUN
dpc-1105	5	37	.	.	PUNCT
dpc-1105	6	1	case	case	NOUN
dpc-1105	6	2	presentation	presentation	NOUN
dpc-1105	6	3	a	a	DET
dpc-1105	6	4	47	47	NUM
dpc-1105	6	5	-	-	PUNCT
dpc-1105	6	6	year	year	NOUN
dpc-1105	6	7	-	-	PUNCT
dpc-1105	6	8	old	old	ADJ
dpc-1105	6	9	woman	woman	NOUN
dpc-1105	6	10	presented	present	VERB
dpc-1105	6	11	with	with	ADP
dpc-1105	6	12	a	a	DET
dpc-1105	6	13	30	30	NUM
dpc-1105	6	14	-	-	PUNCT
dpc-1105	6	15	year	year	NOUN
dpc-1105	6	16	history	history	NOUN
dpc-1105	6	17	of	of	ADP
dpc-1105	6	18	psoriasis	psoriasis	NOUN
dpc-1105	6	19	vulgaris	vulgaris	NOUN
dpc-1105	6	20	without	without	ADP
dpc-1105	6	21	psoriatic	psoriatic	ADJ
dpc-1105	6	22	arthritis	arthritis	NOUN
dpc-1105	6	23	or	or	CCONJ
dpc-1105	6	24	other	other	ADJ
dpc-1105	6	25	comorbidities	comorbiditie	NOUN
dpc-1105	6	26	.	.	PUNCT
dpc-1105	7	1	she	she	PRON
dpc-1105	7	2	was	be	AUX
dpc-1105	7	3	previously	previously	ADV
dpc-1105	7	4	treated	treat	VERB
dpc-1105	7	5	with	with	ADP
dpc-1105	7	6	methotrexate	methotrexate	NOUN
dpc-1105	7	7	and	and	CCONJ
dpc-1105	7	8	puva	puva	PROPN
dpc-1105	7	9	but	but	CCONJ
dpc-1105	7	10	had	have	VERB
dpc-1105	7	11	hepatotoxicity	hepatotoxicity	NOUN
dpc-1105	7	12	and	and	CCONJ
dpc-1105	7	13	minimal	minimal	ADJ
dpc-1105	7	14	response	response	NOUN
dpc-1105	7	15	with	with	ADP
dpc-1105	7	16	uvb	uvb	ADJ
dpc-1105	7	17	narrowband	narrowband	NOUN
dpc-1105	7	18	.	.	PUNCT
dpc-1105	8	1	at	at	ADP
dpc-1105	8	2	first	first	ADJ
dpc-1105	8	3	visit	visit	NOUN
dpc-1105	8	4	,	,	PUNCT
dpc-1105	8	5	the	the	DET
dpc-1105	8	6	patient	patient	NOUN
dpc-1105	8	7	revealed	reveal	VERB
dpc-1105	8	8	pasi	pasi	NOUN
dpc-1105	8	9	23.7	23.7	NUM
dpc-1105	8	10	,	,	PUNCT
dpc-1105	8	11	dermatology	dermatology	NOUN
dpc-1105	8	12	life	life	NOUN
dpc-1105	8	13	quality	quality	NOUN
dpc-1105	8	14	index	index	NOUN
dpc-1105	8	15	(	(	PUNCT
dpc-1105	8	16	dlqi	dlqi	ADJ
dpc-1105	8	17	)	)	PUNCT
dpc-1105	8	18	30	30	NUM
dpc-1105	8	19	,	,	PUNCT
dpc-1105	8	20	body	body	NOUN
dpc-1105	8	21	surface	surface	NOUN
dpc-1105	8	22	area	area	NOUN
dpc-1105	8	23	(	(	PUNCT
dpc-1105	8	24	bsa	bsa	PROPN
dpc-1105	8	25	)	)	PUNCT
dpc-1105	8	26	30	30	NUM
dpc-1105	8	27	,	,	PUNCT
dpc-1105	8	28	and	and	CCONJ
dpc-1105	8	29	body	body	NOUN
dpc-1105	8	30	weight	weight	NOUN
dpc-1105	8	31	80	80	NUM
dpc-1105	8	32	kg	kg	NOUN
dpc-1105	8	33	(	(	PUNCT
dpc-1105	8	34	figure	figure	NOUN
dpc-1105	8	35	1	1	NUM
dpc-1105	8	36	)	)	PUNCT
dpc-1105	8	37	and	and	CCONJ
dpc-1105	8	38	was	be	AUX
dpc-1105	8	39	subsequently	subsequently	ADV
dpc-1105	8	40	secukinumab	secukinumab	NOUN
dpc-1105	8	41	:	:	PUNCT
dpc-1105	8	42	rapid	rapid	ADJ
dpc-1105	8	43	efficacy	efficacy	NOUN
dpc-1105	8	44	in	in	ADP
dpc-1105	8	45	psoriasis	psoriasis	NOUN
dpc-1105	8	46	after	after	ADP
dpc-1105	8	47	primary	primary	ADJ
dpc-1105	8	48	failure	failure	NOUN
dpc-1105	8	49	with	with	ADP
dpc-1105	8	50	ustekinumab	ustekinumab	NOUN
dpc-1105	8	51	and	and	CCONJ
dpc-1105	8	52	adalimumab	adalimumab	NOUN
dpc-1105	8	53	aline	aline	PROPN
dpc-1105	8	54	lissa	lissa	PROPN
dpc-1105	8	55	okita1	okita1	PROPN
dpc-1105	8	56	,	,	PUNCT
dpc-1105	8	57	tatiane	tatiane	PROPN
dpc-1105	8	58	benini1	benini1	PROPN
dpc-1105	8	59	,	,	PUNCT
dpc-1105	8	60	denise	denise	PROPN
dpc-1105	8	61	reis	reis	NOUN
dpc-1105	8	62	longhi1	longhi1	VERB
dpc-1105	8	63	1	1	NUM
dpc-1105	8	64	department	department	NOUN
dpc-1105	8	65	of	of	ADP
dpc-1105	8	66	dermatology	dermatology	NOUN
dpc-1105	8	67	,	,	PUNCT
dpc-1105	8	68	universidade	universidade	PROPN
dpc-1105	8	69	de	de	PROPN
dpc-1105	8	70	mogi	mogi	PROPN
dpc-1105	8	71	das	das	PROPN
dpc-1105	8	72	cruzes	cruzes	PROPN
dpc-1105	8	73	,	,	PUNCT
dpc-1105	8	74	são	são	PROPN
dpc-1105	8	75	paulo	paulo	PROPN
dpc-1105	8	76	,	,	PUNCT
dpc-1105	8	77	brazil	brazil	PROPN
dpc-1105	8	78	key	key	ADJ
dpc-1105	8	79	words	word	NOUN
dpc-1105	8	80	:	:	PUNCT
dpc-1105	8	81	severe	severe	ADJ
dpc-1105	8	82	psoriasis	psoriasis	NOUN
dpc-1105	8	83	,	,	PUNCT
dpc-1105	8	84	biologics	biologic	NOUN
dpc-1105	8	85	,	,	PUNCT
dpc-1105	8	86	secukinumab	secukinumab	NOUN
dpc-1105	8	87	,	,	PUNCT
dpc-1105	8	88	adalimumab	adalimumab	NOUN
dpc-1105	8	89	,	,	PUNCT
dpc-1105	8	90	ustekinumab	ustekinumab	NOUN
dpc-1105	8	91	citation	citation	NOUN
dpc-1105	8	92	:	:	PUNCT
dpc-1105	8	93	okita	okita	PROPN
dpc-1105	8	94	al	al	PROPN
dpc-1105	8	95	,	,	PUNCT
dpc-1105	8	96	benini	benini	NOUN
dpc-1105	8	97	t	t	PROPN
dpc-1105	8	98	,	,	PUNCT
dpc-1105	8	99	reis	reis	PROPN
dpc-1105	8	100	longhi	longhi	PROPN
dpc-1105	8	101	d.	d.	PROPN
dpc-1105	8	102	secukinumab	secukinumab	PROPN
dpc-1105	8	103	:	:	PUNCT
dpc-1105	8	104	rapid	rapid	ADJ
dpc-1105	8	105	efficacy	efficacy	NOUN
dpc-1105	8	106	in	in	ADP
dpc-1105	8	107	psoriasis	psoriasis	NOUN
dpc-1105	8	108	after	after	ADP
dpc-1105	8	109	primary	primary	ADJ
dpc-1105	8	110	failure	failure	NOUN
dpc-1105	8	111	with	with	ADP
dpc-1105	8	112	ustekinumab	ustekinumab	NOUN
dpc-1105	8	113	and	and	CCONJ
dpc-1105	8	114	adalimumab	adalimumab	NOUN
dpc-1105	8	115	.	.	PUNCT
dpc-1105	9	1	dermatol	dermatol	NOUN
dpc-1105	9	2	pract	pract	PROPN
dpc-1105	9	3	concept	concept	NOUN
dpc-1105	9	4	.	.	PUNCT
dpc-1105	10	1	2020;10(4):e2020102	2020;10(4):e2020102	NUM
dpc-1105	10	2	.	.	X
dpc-1105	10	3	doi	doi	NOUN
dpc-1105	10	4	:	:	PUNCT
dpc-1105	10	5	https://doi.org/10.5826/dpc.1004a102	https://doi.org/10.5826/dpc.1004a102	NOUN
dpc-1105	10	6	accepted	accept	VERB
dpc-1105	10	7	:	:	PUNCT
dpc-1105	10	8	may	may	AUX
dpc-1105	10	9	28	28	NUM
dpc-1105	10	10	,	,	PUNCT
dpc-1105	10	11	2020	2020	NUM
dpc-1105	10	12	;	;	PUNCT
dpc-1105	10	13	published	publish	VERB
dpc-1105	10	14	:	:	PUNCT
dpc-1105	10	15	october	october	PROPN
dpc-1105	10	16	26	26	NUM
dpc-1105	10	17	,	,	PUNCT
dpc-1105	10	18	2020	2020	NUM
dpc-1105	10	19	copyright	copyright	NOUN
dpc-1105	10	20	:	:	PUNCT
dpc-1105	11	1	©	©	PROPN
dpc-1105	11	2	2020	2020	NUM
dpc-1105	11	3	okita	okita	PROPN
dpc-1105	11	4	et	et	PROPN
dpc-1105	11	5	al	al	PROPN
dpc-1105	11	6	.	.	PUNCT
dpc-1105	12	1	this	this	PRON
dpc-1105	12	2	is	be	AUX
dpc-1105	12	3	an	an	DET
dpc-1105	12	4	open	open	ADJ
dpc-1105	12	5	-	-	PUNCT
dpc-1105	12	6	access	access	NOUN
dpc-1105	12	7	article	article	NOUN
dpc-1105	12	8	distributed	distribute	VERB
dpc-1105	12	9	under	under	ADP
dpc-1105	12	10	the	the	DET
dpc-1105	12	11	terms	term	NOUN
dpc-1105	12	12	of	of	ADP
dpc-1105	12	13	the	the	DET
dpc-1105	12	14	creative	creative	ADJ
dpc-1105	12	15	commons	common	NOUN
dpc-1105	12	16	attribution	attribution	NOUN
dpc-1105	12	17	license	license	NOUN
dpc-1105	12	18	bync-4.0	bync-4.0	NOUN
dpc-1105	12	19	,	,	PUNCT
dpc-1105	12	20	which	which	PRON
dpc-1105	12	21	permits	permit	VERB
dpc-1105	12	22	unrestricted	unrestricted	ADJ
dpc-1105	12	23	noncommercial	noncommercial	ADJ
dpc-1105	12	24	use	use	NOUN
dpc-1105	12	25	,	,	PUNCT
dpc-1105	12	26	distribution	distribution	NOUN
dpc-1105	12	27	,	,	PUNCT
dpc-1105	12	28	and	and	CCONJ
dpc-1105	12	29	reproduction	reproduction	NOUN
dpc-1105	12	30	in	in	ADP
dpc-1105	12	31	any	any	DET
dpc-1105	12	32	medium	medium	NOUN
dpc-1105	12	33	,	,	PUNCT
dpc-1105	12	34	provided	provide	VERB
dpc-1105	12	35	the	the	DET
dpc-1105	12	36	original	original	ADJ
dpc-1105	12	37	author	author	NOUN
dpc-1105	12	38	and	and	CCONJ
dpc-1105	12	39	source	source	NOUN
dpc-1105	12	40	are	be	AUX
dpc-1105	12	41	credited	credit	VERB
dpc-1105	12	42	.	.	PUNCT
dpc-1105	13	1	funding	funding	NOUN
dpc-1105	13	2	:	:	PUNCT
dpc-1105	13	3	none	none	NOUN
dpc-1105	13	4	.	.	PUNCT
dpc-1105	14	1	competing	compete	VERB
dpc-1105	14	2	interests	interest	NOUN
dpc-1105	14	3	:	:	PUNCT
dpc-1105	14	4	the	the	DET
dpc-1105	14	5	authors	author	NOUN
dpc-1105	14	6	have	have	VERB
dpc-1105	14	7	no	no	DET
dpc-1105	14	8	conflicts	conflict	NOUN
dpc-1105	14	9	of	of	ADP
dpc-1105	14	10	interest	interest	NOUN
dpc-1105	14	11	to	to	PART
dpc-1105	14	12	disclose	disclose	VERB
dpc-1105	14	13	.	.	PUNCT
dpc-1105	15	1	authorship	authorship	NOUN
dpc-1105	15	2	:	:	PUNCT
dpc-1105	15	3	all	all	DET
dpc-1105	15	4	authors	author	NOUN
dpc-1105	15	5	have	have	AUX
dpc-1105	15	6	contributed	contribute	VERB
dpc-1105	15	7	significantly	significantly	ADV
dpc-1105	15	8	to	to	ADP
dpc-1105	15	9	this	this	DET
dpc-1105	15	10	publication	publication	NOUN
dpc-1105	15	11	.	.	PUNCT
dpc-1105	16	1	corresponding	correspond	VERB
dpc-1105	16	2	author	author	NOUN
dpc-1105	16	3	:	:	PUNCT
dpc-1105	16	4	aline	aline	PROPN
dpc-1105	16	5	lissa	lissa	PROPN
dpc-1105	16	6	okita	okita	PROPN
dpc-1105	16	7	,	,	PUNCT
dpc-1105	16	8	md	md	PROPN
dpc-1105	16	9	,	,	PUNCT
dpc-1105	16	10	department	department	PROPN
dpc-1105	16	11	of	of	ADP
dpc-1105	16	12	dermatology	dermatology	NOUN
dpc-1105	16	13	from	from	ADP
dpc-1105	16	14	universidade	universidade	PROPN
dpc-1105	16	15	de	de	PROPN
dpc-1105	16	16	mogi	mogi	PROPN
dpc-1105	16	17	das	das	PROPN
dpc-1105	16	18	cruzes	cruzes	PROPN
dpc-1105	16	19	,	,	PUNCT
dpc-1105	16	20	ave	ave	PROPN
dpc-1105	16	21	dr	dr	PROPN
dpc-1105	16	22	cândido	cândido	PROPN
dpc-1105	16	23	x	x	PUNCT
dpc-1105	16	24	de	de	PROPN
dpc-1105	16	25	almeida	almeida	PROPN
dpc-1105	16	26	e	e	PROPN
dpc-1105	16	27	souza	souza	PROPN
dpc-1105	16	28	,	,	PUNCT
dpc-1105	16	29	200	200	NUM
dpc-1105	16	30	,	,	PUNCT
dpc-1105	16	31	são	são	PROPN
dpc-1105	16	32	paulo	paulo	PROPN
dpc-1105	16	33	,	,	PUNCT
dpc-1105	16	34	brazil	brazil	PROPN
dpc-1105	16	35	.	.	PUNCT
dpc-1105	17	1	email	email	NOUN
dpc-1105	17	2	:	:	PUNCT
dpc-1105	17	3	alinelissaokita@gmail.com	alinelissaokita@gmail.com	X
dpc-1105	18	1	figure	figure	NOUN
dpc-1105	18	2	1	1	NUM
dpc-1105	18	3	.	.	PUNCT
dpc-1105	19	1	clinical	clinical	ADJ
dpc-1105	19	2	presentation	presentation	NOUN
dpc-1105	19	3	prior	prior	ADV
dpc-1105	19	4	to	to	ADP
dpc-1105	19	5	ustekinumab	ustekinumab	NOUN
dpc-1105	19	6	treatment	treatment	NOUN
dpc-1105	19	7	.	.	PUNCT
dpc-1105	20	1	2	2	NUM
dpc-1105	20	2	letter	letter	NOUN
dpc-1105	20	3	|	|	ADV
dpc-1105	20	4	dermatol	dermatol	ADJ
dpc-1105	20	5	pract	pract	NOUN
dpc-1105	20	6	concept	concept	NOUN
dpc-1105	20	7	2020;10(4):2020102	2020;10(4):2020102	NUM
dpc-1105	20	8	300	300	NUM
dpc-1105	20	9	or	or	CCONJ
dpc-1105	20	10	150	150	NUM
dpc-1105	20	11	mg	mg	NUM
dpc-1105	20	12	.	.	PUNCT
dpc-1105	21	1	the	the	DET
dpc-1105	21	2	3	3	NUM
dpc-1105	21	3	groups	group	NOUN
dpc-1105	21	4	were	be	AUX
dpc-1105	21	5	:	:	PUNCT
dpc-1105	21	6	patients	patient	NOUN
dpc-1105	21	7	with	with	ADP
dpc-1105	21	8	primary	primary	ADJ
dpc-1105	21	9	failure	failure	NOUN
dpc-1105	21	10	to	to	ADP
dpc-1105	21	11	anti	anti	ADJ
dpc-1105	21	12	-	-	NOUN
dpc-1105	21	13	tnfα	tnfα	NOUN
dpc-1105	21	14	;	;	PUNCT
dpc-1105	21	15	patients	patient	NOUN
dpc-1105	21	16	with	with	ADP
dpc-1105	21	17	secondary	secondary	ADJ
dpc-1105	21	18	failure	failure	NOUN
dpc-1105	21	19	to	to	ADP
dpc-1105	21	20	anti	anti	ADJ
dpc-1105	21	21	-	-	NOUN
dpc-1105	21	22	tnfα	tnfα	NOUN
dpc-1105	21	23	;	;	PUNCT
dpc-1105	21	24	and	and	CCONJ
dpc-1105	21	25	patients	patient	NOUN
dpc-1105	21	26	who	who	PRON
dpc-1105	21	27	failed	fail	VERB
dpc-1105	21	28	with	with	ADP
dpc-1105	21	29	more	more	ADJ
dpc-1105	21	30	than	than	ADP
dpc-1105	21	31	one	one	NUM
dpc-1105	21	32	anti	anti	ADJ
dpc-1105	21	33	-	-	NOUN
dpc-1105	21	34	tnfα	tnfα	NOUN
dpc-1105	21	35	.	.	PUNCT
dpc-1105	22	1	the	the	DET
dpc-1105	22	2	patients	patient	NOUN
dpc-1105	22	3	in	in	ADP
dpc-1105	22	4	the	the	DET
dpc-1105	22	5	3	3	NUM
dpc-1105	22	6	groups	group	NOUN
dpc-1105	22	7	achieved	achieve	VERB
dpc-1105	22	8	statistically	statistically	ADV
dpc-1105	22	9	significant	significant	ADJ
dpc-1105	22	10	rates	rate	NOUN
dpc-1105	22	11	of	of	ADP
dpc-1105	22	12	pasi	pasi	NOUN
dpc-1105	22	13	75	75	NUM
dpc-1105	22	14	using	use	VERB
dpc-1105	22	15	secukinumab	secukinumab	NOUN
dpc-1105	22	16	300	300	NUM
dpc-1105	22	17	mg	mg	NOUN
dpc-1105	23	1	[	[	X
dpc-1105	23	2	2	2	NUM
dpc-1105	23	3	]	]	PUNCT
dpc-1105	23	4	.	.	PUNCT
dpc-1105	24	1	magnano	magnano	PROPN
dpc-1105	24	2	et	et	PROPN
dpc-1105	24	3	al	al	PROPN
dpc-1105	24	4	reported	report	VERB
dpc-1105	24	5	on	on	ADP
dpc-1105	24	6	16	16	NUM
dpc-1105	24	7	psoriatic	psoriatic	ADJ
dpc-1105	24	8	patients	patient	NOUN
dpc-1105	24	9	previously	previously	ADV
dpc-1105	24	10	treated	treat	VERB
dpc-1105	24	11	with	with	ADP
dpc-1105	24	12	more	more	ADJ
dpc-1105	24	13	than	than	ADP
dpc-1105	24	14	1	1	NUM
dpc-1105	24	15	systemic	systemic	ADJ
dpc-1105	24	16	or	or	CCONJ
dpc-1105	24	17	biologic	biologic	ADJ
dpc-1105	24	18	agent	agent	NOUN
dpc-1105	24	19	,	,	PUNCT
dpc-1105	24	20	without	without	ADP
dpc-1105	24	21	control	control	NOUN
dpc-1105	24	22	of	of	ADP
dpc-1105	24	23	skin	skin	NOUN
dpc-1105	24	24	lesions	lesion	NOUN
dpc-1105	24	25	.	.	PUNCT
dpc-1105	25	1	these	these	DET
dpc-1105	25	2	patients	patient	NOUN
dpc-1105	25	3	were	be	AUX
dpc-1105	25	4	treated	treat	VERB
dpc-1105	25	5	with	with	ADP
dpc-1105	25	6	secukinumab	secukinumab	NOUN
dpc-1105	25	7	,	,	PUNCT
dpc-1105	25	8	and	and	CCONJ
dpc-1105	25	9	8	8	NUM
dpc-1105	25	10	of	of	ADP
dpc-1105	25	11	them	they	PRON
dpc-1105	25	12	obtained	obtain	VERB
dpc-1105	25	13	a	a	DET
dpc-1105	25	14	complete	complete	ADJ
dpc-1105	25	15	clearance	clearance	NOUN
dpc-1105	25	16	(	(	PUNCT
dpc-1105	25	17	pasi	pasi	NOUN
dpc-1105	25	18	100	100	NUM
dpc-1105	25	19	)	)	PUNCT
dpc-1105	25	20	,	,	PUNCT
dpc-1105	25	21	6	6	NUM
dpc-1105	25	22	patients	patient	NOUN
dpc-1105	25	23	presented	present	VERB
dpc-1105	25	24	pasi	pasi	NOUN
dpc-1105	25	25	90	90	NUM
dpc-1105	25	26	,	,	PUNCT
dpc-1105	25	27	and	and	CCONJ
dpc-1105	25	28	2	2	NUM
dpc-1105	25	29	patients	patient	NOUN
dpc-1105	25	30	showed	show	VERB
dpc-1105	25	31	pasi	pasi	NOUN
dpc-1105	25	32	75	75	NUM
dpc-1105	25	33	.	.	PUNCT
dpc-1105	26	1	all	all	DET
dpc-1105	26	2	patients	patient	NOUN
dpc-1105	26	3	presented	present	VERB
dpc-1105	26	4	improvement	improvement	NOUN
dpc-1105	26	5	in	in	ADP
dpc-1105	26	6	the	the	DET
dpc-1105	26	7	dlqi	dlqi	NOUN
dpc-1105	26	8	[	[	X
dpc-1105	26	9	3	3	NUM
dpc-1105	26	10	]	]	PUNCT
dpc-1105	26	11	.	.	PUNCT
dpc-1105	27	1	in	in	ADP
dpc-1105	27	2	addition	addition	NOUN
dpc-1105	27	3	,	,	PUNCT
dpc-1105	27	4	a	a	DET
dpc-1105	27	5	case	case	NOUN
dpc-1105	27	6	of	of	ADP
dpc-1105	27	7	successful	successful	ADJ
dpc-1105	27	8	treatment	treatment	NOUN
dpc-1105	27	9	with	with	ADP
dpc-1105	27	10	secukinumab	secukinumab	NOUN
dpc-1105	27	11	in	in	ADP
dpc-1105	27	12	recalcitrant	recalcitrant	ADJ
dpc-1105	27	13	psoriatic	psoriatic	ADJ
dpc-1105	27	14	arthritis	arthritis	NOUN
dpc-1105	27	15	treated	treat	VERB
dpc-1105	27	16	previously	previously	ADV
dpc-1105	27	17	with	with	ADP
dpc-1105	27	18	2	2	NUM
dpc-1105	27	19	anti	anti	ADJ
dpc-1105	27	20	-	-	ADJ
dpc-1105	27	21	tnf	tnf	ADJ
dpc-1105	27	22	drugs	drug	NOUN
dpc-1105	27	23	was	be	AUX
dpc-1105	27	24	reported	report	VERB
dpc-1105	27	25	[	[	X
dpc-1105	27	26	4	4	NUM
dpc-1105	27	27	]	]	PUNCT
dpc-1105	27	28	.	.	PUNCT
dpc-1105	28	1	the	the	DET
dpc-1105	28	2	case	case	NOUN
dpc-1105	28	3	reported	report	VERB
dpc-1105	28	4	here	here	ADV
dpc-1105	28	5	was	be	AUX
dpc-1105	28	6	exposed	expose	VERB
dpc-1105	28	7	to	to	ADP
dpc-1105	28	8	multiple	multiple	ADJ
dpc-1105	28	9	systemic	systemic	ADJ
dpc-1105	28	10	treatments	treatment	NOUN
dpc-1105	28	11	resulting	result	VERB
dpc-1105	28	12	in	in	ADP
dpc-1105	28	13	inadequate	inadequate	ADJ
dpc-1105	28	14	disease	disease	NOUN
dpc-1105	28	15	control	control	NOUN
dpc-1105	28	16	and	and	CCONJ
dpc-1105	28	17	adverse	adverse	ADJ
dpc-1105	28	18	events	event	NOUN
dpc-1105	28	19	that	that	PRON
dpc-1105	28	20	led	lead	VERB
dpc-1105	28	21	to	to	ADP
dpc-1105	28	22	discontinuation	discontinuation	NOUN
dpc-1105	28	23	of	of	ADP
dpc-1105	28	24	therapies	therapy	NOUN
dpc-1105	28	25	.	.	PUNCT
dpc-1105	29	1	she	she	PRON
dpc-1105	29	2	failed	fail	VERB
dpc-1105	29	3	to	to	PART
dpc-1105	29	4	respond	respond	VERB
dpc-1105	29	5	to	to	ADP
dpc-1105	29	6	both	both	DET
dpc-1105	29	7	anti	anti	ADJ
dpc-1105	29	8	-	-	ADJ
dpc-1105	29	9	tnfα	tnfα	ADJ
dpc-1105	29	10	and	and	CCONJ
dpc-1105	29	11	anti	anti	ADJ
dpc-1105	29	12	-	-	ADJ
dpc-1105	29	13	il12/23	il12/23	ADJ
dpc-1105	29	14	drugs	drug	NOUN
dpc-1105	29	15	but	but	CCONJ
dpc-1105	29	16	reached	reach	VERB
dpc-1105	29	17	pasi	pasi	NOUN
dpc-1105	29	18	100	100	NUM
dpc-1105	29	19	in	in	ADP
dpc-1105	29	20	8	8	NUM
dpc-1105	29	21	weeks	week	NOUN
dpc-1105	29	22	with	with	ADP
dpc-1105	29	23	secukinumab	secukinumab	NOUN
dpc-1105	29	24	without	without	ADP
dpc-1105	29	25	any	any	DET
dpc-1105	29	26	adverse	adverse	ADJ
dpc-1105	29	27	effects	effect	NOUN
dpc-1105	29	28	.	.	PUNCT
dpc-1105	30	1	this	this	PRON
dpc-1105	30	2	indicates	indicate	VERB
dpc-1105	30	3	that	that	SCONJ
dpc-1105	30	4	each	each	DET
dpc-1105	30	5	patient	patient	NOUN
dpc-1105	30	6	may	may	AUX
dpc-1105	30	7	have	have	VERB
dpc-1105	30	8	a	a	DET
dpc-1105	30	9	specific	specific	ADJ
dpc-1105	30	10	behavior	behavior	NOUN
dpc-1105	30	11	in	in	ADP
dpc-1105	30	12	the	the	DET
dpc-1105	30	13	disease	disease	NOUN
dpc-1105	30	14	pathway	pathway	NOUN
dpc-1105	30	15	and	and	CCONJ
dpc-1105	30	16	might	might	AUX
dpc-1105	30	17	respond	respond	VERB
dpc-1105	30	18	better	well	ADV
dpc-1105	30	19	to	to	ADP
dpc-1105	30	20	certain	certain	ADJ
dpc-1105	30	21	drugs	drug	NOUN
dpc-1105	30	22	.	.	PUNCT
dpc-1105	31	1	further	further	ADJ
dpc-1105	31	2	studies	study	NOUN
dpc-1105	31	3	are	be	AUX
dpc-1105	31	4	needed	need	VERB
dpc-1105	31	5	to	to	PART
dpc-1105	31	6	determine	determine	VERB
dpc-1105	31	7	which	which	DET
dpc-1105	31	8	factors	factor	NOUN
dpc-1105	31	9	are	be	AUX
dpc-1105	31	10	essential	essential	ADJ
dpc-1105	31	11	to	to	PART
dpc-1105	31	12	define	define	VERB
dpc-1105	31	13	the	the	DET
dpc-1105	31	14	biologic	biologic	NOUN
dpc-1105	31	15	of	of	ADP
dpc-1105	31	16	choice	choice	NOUN
dpc-1105	31	17	.	.	PUNCT
dpc-1105	32	1	treated	treat	VERB
dpc-1105	32	2	with	with	ADP
dpc-1105	32	3	ustekinumab	ustekinumab	NOUN
dpc-1105	32	4	45	45	NUM
dpc-1105	32	5	mg	mg	NOUN
dpc-1105	32	6	for	for	ADP
dpc-1105	32	7	6	6	NUM
dpc-1105	32	8	months	month	NOUN
dpc-1105	32	9	with	with	ADP
dpc-1105	32	10	no	no	DET
dpc-1105	32	11	response	response	NOUN
dpc-1105	32	12	.	.	PUNCT
dpc-1105	33	1	then	then	ADV
dpc-1105	33	2	she	she	PRON
dpc-1105	33	3	received	receive	VERB
dpc-1105	33	4	adalimumab	adalimumab	NOUN
dpc-1105	33	5	,	,	PUNCT
dpc-1105	33	6	but	but	CCONJ
dpc-1105	33	7	symptoms	symptom	NOUN
dpc-1105	33	8	worsened	worsen	VERB
dpc-1105	33	9	with	with	ADP
dpc-1105	33	10	an	an	DET
dpc-1105	33	11	increased	increase	VERB
dpc-1105	33	12	number	number	NOUN
dpc-1105	33	13	of	of	ADP
dpc-1105	33	14	lesions	lesion	NOUN
dpc-1105	33	15	and	and	CCONJ
dpc-1105	33	16	intense	intense	ADJ
dpc-1105	33	17	itching	itching	NOUN
dpc-1105	33	18	(	(	PUNCT
dpc-1105	33	19	pasi	pasi	NOUN
dpc-1105	33	20	33.6	33.6	NUM
dpc-1105	33	21	,	,	PUNCT
dpc-1105	33	22	dlqi	dlqi	VERB
dpc-1105	33	23	30	30	NUM
dpc-1105	33	24	,	,	PUNCT
dpc-1105	33	25	bsa	bsa	PROPN
dpc-1105	33	26	78	78	NUM
dpc-1105	33	27	)	)	PUNCT
dpc-1105	33	28	(	(	PUNCT
dpc-1105	33	29	figures	figure	NOUN
dpc-1105	33	30	2a	2a	NUM
dpc-1105	33	31	and	and	CCONJ
dpc-1105	33	32	3a	3a	NUM
dpc-1105	33	33	)	)	PUNCT
dpc-1105	33	34	.	.	PUNCT
dpc-1105	34	1	after	after	ADP
dpc-1105	34	2	that	that	PRON
dpc-1105	34	3	,	,	PUNCT
dpc-1105	34	4	she	she	PRON
dpc-1105	34	5	received	receive	VERB
dpc-1105	34	6	secukinumab	secukinumab	NOUN
dpc-1105	34	7	300	300	NUM
dpc-1105	34	8	mg	mg	NOUN
dpc-1105	34	9	at	at	ADP
dpc-1105	34	10	weeks	week	NOUN
dpc-1105	34	11	0	0	NUM
dpc-1105	34	12	,	,	PUNCT
dpc-1105	34	13	1	1	NUM
dpc-1105	34	14	,	,	PUNCT
dpc-1105	34	15	2	2	NUM
dpc-1105	34	16	and	and	CCONJ
dpc-1105	34	17	3	3	NUM
dpc-1105	34	18	,	,	PUNCT
dpc-1105	34	19	4	4	NUM
dpc-1105	34	20	achieving	achieve	VERB
dpc-1105	34	21	pasi	pasi	NOUN
dpc-1105	34	22	75	75	NUM
dpc-1105	34	23	at	at	ADP
dpc-1105	34	24	week	week	NOUN
dpc-1105	34	25	5	5	NUM
dpc-1105	34	26	(	(	PUNCT
dpc-1105	34	27	figures	figure	NOUN
dpc-1105	34	28	2b	2b	NOUN
dpc-1105	34	29	and	and	CCONJ
dpc-1105	34	30	3b	3b	NUM
dpc-1105	34	31	)	)	PUNCT
dpc-1105	34	32	and	and	CCONJ
dpc-1105	34	33	pasi	pasi	NOUN
dpc-1105	34	34	100	100	NUM
dpc-1105	34	35	and	and	CCONJ
dpc-1105	34	36	dlqi	dlqi	VERB
dpc-1105	34	37	0	0	PUNCT
dpc-1105	35	1	at	at	ADP
dpc-1105	35	2	week	week	NOUN
dpc-1105	35	3	8	8	NUM
dpc-1105	35	4	.	.	PUNCT
dpc-1105	36	1	conclusions	conclusion	NOUN
dpc-1105	36	2	studies	study	NOUN
dpc-1105	36	3	on	on	ADP
dpc-1105	36	4	secukinumab	secukinumab	NOUN
dpc-1105	36	5	have	have	AUX
dpc-1105	36	6	demonstrated	demonstrate	VERB
dpc-1105	36	7	rapid	rapid	ADJ
dpc-1105	36	8	and	and	CCONJ
dpc-1105	36	9	high	high	ADJ
dpc-1105	36	10	efficacy	efficacy	NOUN
dpc-1105	36	11	in	in	ADP
dpc-1105	36	12	the	the	DET
dpc-1105	36	13	treatment	treatment	NOUN
dpc-1105	36	14	of	of	ADP
dpc-1105	36	15	psoriasis	psoriasis	NOUN
dpc-1105	36	16	,	,	PUNCT
dpc-1105	36	17	and	and	CCONJ
dpc-1105	36	18	bio	bio	ADJ
dpc-1105	36	19	-	-	ADJ
dpc-1105	36	20	naïve	naïve	ADJ
dpc-1105	36	21	patients	patient	NOUN
dpc-1105	36	22	achieved	achieve	VERB
dpc-1105	36	23	higher	high	ADJ
dpc-1105	36	24	scores	score	NOUN
dpc-1105	36	25	,	,	PUNCT
dpc-1105	36	26	pasi	pasi	NOUN
dpc-1105	36	27	90	90	NUM
dpc-1105	36	28	,	,	PUNCT
dpc-1105	36	29	than	than	ADP
dpc-1105	36	30	those	those	PRON
dpc-1105	36	31	previously	previously	ADV
dpc-1105	36	32	exposed	expose	VERB
dpc-1105	36	33	to	to	ADP
dpc-1105	36	34	treatment	treatment	NOUN
dpc-1105	36	35	with	with	ADP
dpc-1105	36	36	biologics	biologic	NOUN
dpc-1105	36	37	.	.	PUNCT
dpc-1105	37	1	however	however	ADV
dpc-1105	37	2	,	,	PUNCT
dpc-1105	37	3	many	many	ADJ
dpc-1105	37	4	authors	author	NOUN
dpc-1105	37	5	reported	report	VERB
dpc-1105	37	6	successful	successful	ADJ
dpc-1105	37	7	treatment	treatment	NOUN
dpc-1105	37	8	with	with	ADP
dpc-1105	37	9	secukinumab	secukinumab	NOUN
dpc-1105	37	10	after	after	ADP
dpc-1105	37	11	biological	biological	ADJ
dpc-1105	37	12	exposure	exposure	NOUN
dpc-1105	37	13	.	.	PUNCT
dpc-1105	38	1	in	in	ADP
dpc-1105	38	2	one	one	NUM
dpc-1105	38	3	series	series	NOUN
dpc-1105	38	4	of	of	ADP
dpc-1105	38	5	6	6	NUM
dpc-1105	38	6	patients	patient	NOUN
dpc-1105	38	7	,	,	PUNCT
dpc-1105	38	8	patients	patient	NOUN
dpc-1105	38	9	exhibited	exhibit	VERB
dpc-1105	38	10	efficacy	efficacy	NOUN
dpc-1105	38	11	with	with	ADP
dpc-1105	38	12	secukinumab	secukinumab	NOUN
dpc-1105	38	13	after	after	ADP
dpc-1105	38	14	failure	failure	NOUN
dpc-1105	38	15	with	with	ADP
dpc-1105	38	16	ustekinumab	ustekinumab	NOUN
dpc-1105	38	17	.	.	PUNCT
dpc-1105	39	1	four	four	NUM
dpc-1105	39	2	patients	patient	NOUN
dpc-1105	39	3	had	have	VERB
dpc-1105	39	4	primary	primary	ADJ
dpc-1105	39	5	failure	failure	NOUN
dpc-1105	39	6	with	with	ADP
dpc-1105	39	7	ustekinumab	ustekinumab	NOUN
dpc-1105	39	8	and	and	CCONJ
dpc-1105	39	9	2	2	NUM
dpc-1105	39	10	patients	patient	NOUN
dpc-1105	39	11	experienced	experience	VERB
dpc-1105	39	12	secondary	secondary	ADJ
dpc-1105	39	13	failure	failure	NOUN
dpc-1105	39	14	.	.	PUNCT
dpc-1105	40	1	after	after	ADP
dpc-1105	40	2	12	12	NUM
dpc-1105	40	3	weeks	week	NOUN
dpc-1105	40	4	,	,	PUNCT
dpc-1105	40	5	4	4	NUM
dpc-1105	40	6	patients	patient	NOUN
dpc-1105	40	7	achieved	achieve	VERB
dpc-1105	40	8	pasi	pasi	NOUN
dpc-1105	40	9	90	90	NUM
dpc-1105	40	10	with	with	ADP
dpc-1105	40	11	secukinumab	secukinumab	NOUN
dpc-1105	40	12	[	[	X
dpc-1105	40	13	1	1	NUM
dpc-1105	40	14	]	]	PUNCT
dpc-1105	40	15	.	.	PUNCT
dpc-1105	41	1	another	another	DET
dpc-1105	41	2	study	study	NOUN
dpc-1105	41	3	of	of	ADP
dpc-1105	41	4	235	235	NUM
dpc-1105	41	5	patients	patient	NOUN
dpc-1105	41	6	randomized	randomize	VERB
dpc-1105	41	7	3	3	NUM
dpc-1105	41	8	groups	group	NOUN
dpc-1105	41	9	of	of	ADP
dpc-1105	41	10	anti	anti	ADJ
dpc-1105	41	11	-	-	ADJ
dpc-1105	41	12	tnf	tnf	ADJ
dpc-1105	41	13	nonresponders	nonresponder	NOUN
dpc-1105	41	14	to	to	PART
dpc-1105	41	15	treatment	treatment	VERB
dpc-1105	41	16	with	with	ADP
dpc-1105	41	17	secukinumab	secukinumab	NOUN
dpc-1105	41	18	at	at	ADP
dpc-1105	41	19	figure	figure	NOUN
dpc-1105	41	20	2	2	NUM
dpc-1105	41	21	.	.	PUNCT
dpc-1105	41	22	clinical	clinical	ADJ
dpc-1105	41	23	presentation	presentation	NOUN
dpc-1105	41	24	.	.	PUNCT
dpc-1105	42	1	(	(	PUNCT
dpc-1105	42	2	a	a	X
dpc-1105	42	3	)	)	PUNCT
dpc-1105	42	4	after	after	ADP
dpc-1105	42	5	adalimumab	adalimumab	NOUN
dpc-1105	42	6	treatment	treatment	NOUN
dpc-1105	42	7	.	.	PUNCT
dpc-1105	43	1	(	(	PUNCT
dpc-1105	43	2	b	b	X
dpc-1105	43	3	)	)	PUNCT
dpc-1105	43	4	after	after	ADP
dpc-1105	43	5	5	5	NUM
dpc-1105	43	6	weeks	week	NOUN
dpc-1105	43	7	of	of	ADP
dpc-1105	43	8	secukinumab	secukinumab	NOUN
dpc-1105	43	9	treatment	treatment	NOUN
dpc-1105	43	10	.	.	PUNCT
dpc-1105	44	1	a	a	DET
dpc-1105	44	2	b	b	NUM
dpc-1105	44	3	figure	figure	NOUN
dpc-1105	44	4	3	3	NUM
dpc-1105	44	5	.	.	PUNCT
dpc-1105	44	6	clinical	clinical	ADJ
dpc-1105	44	7	presentation	presentation	NOUN
dpc-1105	44	8	.	.	PUNCT
dpc-1105	45	1	(	(	PUNCT
dpc-1105	45	2	a	a	X
dpc-1105	45	3	)	)	PUNCT
dpc-1105	45	4	after	after	ADP
dpc-1105	45	5	adalimumab	adalimumab	NOUN
dpc-1105	45	6	treatment	treatment	NOUN
dpc-1105	45	7	.	.	PUNCT
dpc-1105	46	1	(	(	PUNCT
dpc-1105	46	2	b	b	X
dpc-1105	46	3	)	)	PUNCT
dpc-1105	46	4	after	after	ADP
dpc-1105	46	5	5	5	NUM
dpc-1105	46	6	weeks	week	NOUN
dpc-1105	46	7	of	of	ADP
dpc-1105	46	8	secukinumab	secukinumab	NOUN
dpc-1105	46	9	treatment	treatment	NOUN
dpc-1105	46	10	.	.	PUNCT
dpc-1105	47	1	a	a	DET
dpc-1105	47	2	b	b	NOUN
dpc-1105	47	3	letter	letter	NOUN
dpc-1105	47	4	|	|	ADV
dpc-1105	47	5	dermatol	dermatol	ADJ
dpc-1105	47	6	pract	pract	NOUN
dpc-1105	47	7	concept	concept	NOUN
dpc-1105	47	8	2020;10(4):2020102	2020;10(4):2020102	NUM
dpc-1105	47	9	3	3	NUM
dpc-1105	47	10	acad	acad	NOUN
dpc-1105	47	11	dermatol	dermatol	NOUN
dpc-1105	47	12	.	.	PUNCT
dpc-1105	48	1	2018;79(3	2018;79(3	NUM
dpc-1105	48	2	suppl	suppl	ADJ
dpc-1105	48	3	1	1	NUM
dpc-1105	48	4	):	):	PUNCT
dpc-1105	48	5	ab256	ab256	PROPN
dpc-1105	48	6	.	.	PUNCT
dpc-1105	49	1	poster	poster	NOUN
dpc-1105	49	2	abstract	abstract	PROPN
dpc-1105	49	3	.	.	PUNCT
dpc-1105	50	1	doi	doi	NOUN
dpc-1105	50	2	:	:	PUNCT
dpc-1105	50	3	10.1016	10.1016	NUM
dpc-1105	50	4	/	/	SYM
dpc-1105	50	5	j.jaad.2018.05.1018	j.jaad.2018.05.1018	PROPN
dpc-1105	50	6	.	.	PUNCT
dpc-1105	51	1	3	3	X
dpc-1105	51	2	.	.	X
dpc-1105	51	3	magnano	magnano	PROPN
dpc-1105	51	4	m	m	PROPN
dpc-1105	51	5	,	,	PUNCT
dpc-1105	51	6	loi	loi	PROPN
dpc-1105	51	7	c	c	NOUN
dpc-1105	51	8	,	,	PUNCT
dpc-1105	51	9	patrizi	patrizi	NOUN
dpc-1105	51	10	a	a	PRON
dpc-1105	51	11	,	,	PUNCT
dpc-1105	51	12	et	et	PROPN
dpc-1105	51	13	al	al	PROPN
dpc-1105	51	14	.	.	PROPN
dpc-1105	51	15	secukinumab	secukinumab	PROPN
dpc-1105	51	16	in	in	ADP
dpc-1105	51	17	multifailure	multifailure	NOUN
dpc-1105	51	18	psoriatic	psoriatic	ADJ
dpc-1105	51	19	patients	patient	NOUN
dpc-1105	51	20	:	:	PUNCT
dpc-1105	51	21	the	the	DET
dpc-1105	51	22	last	last	ADJ
dpc-1105	51	23	hope	hope	NOUN
dpc-1105	51	24	?	?	PUNCT
dpc-1105	52	1	j	j	PROPN
dpc-1105	52	2	dermatolog	dermatolog	PROPN
dpc-1105	52	3	,	,	PUNCT
dpc-1105	52	4	treat	treat	NOUN
dpc-1105	52	5	.	.	PUNCT
dpc-1105	53	1	2018;29(6):583–585	2018;29(6):583–585	X
dpc-1105	53	2	.	.	PUNCT
dpc-1105	54	1	doi	doi	NOUN
dpc-1105	54	2	:	:	PUNCT
dpc-1105	54	3	10.1080/09546634.2018.1427206	10.1080/09546634.2018.1427206	NUM
dpc-1105	54	4	.	.	PUNCT
dpc-1105	55	1	pmid	pmid	NOUN
dpc-1105	55	2	:	:	PUNCT
dpc-1105	55	3	29334270	29334270	NUM
dpc-1105	55	4	.	.	PUNCT
dpc-1105	56	1	4	4	X
dpc-1105	56	2	.	.	X
dpc-1105	57	1	pelechas	pelechas	PROPN
dpc-1105	57	2	e	e	PROPN
dpc-1105	57	3	,	,	PUNCT
dpc-1105	57	4	memi	memi	PROPN
dpc-1105	57	5	t	t	PROPN
dpc-1105	57	6	,	,	PUNCT
dpc-1105	57	7	voulgari	voulgari	X
dpc-1105	57	8	pv	pv	NOUN
dpc-1105	57	9	,	,	PUNCT
dpc-1105	57	10	drosos	drosos	PROPN
dpc-1105	57	11	aa	aa	PROPN
dpc-1105	57	12	.	.	PUNCT
dpc-1105	58	1	a	a	DET
dpc-1105	58	2	case	case	NOUN
dpc-1105	58	3	of	of	ADP
dpc-1105	58	4	recalcitrant	recalcitrant	ADJ
dpc-1105	58	5	psoriatic	psoriatic	ADJ
dpc-1105	58	6	arthritis	arthritis	NOUN
dpc-1105	58	7	to	to	ADP
dpc-1105	58	8	tnf	tnf	PROPN
dpc-1105	58	9	inhibitors	inhibitor	NOUN
dpc-1105	58	10	improved	improve	VERB
dpc-1105	58	11	after	after	ADP
dpc-1105	58	12	administration	administration	NOUN
dpc-1105	58	13	of	of	ADP
dpc-1105	58	14	secukinumab	secukinumab	NOUN
dpc-1105	58	15	,	,	PUNCT
dpc-1105	58	16	an	an	DET
dpc-1105	58	17	il-17a	il-17a	PROPN
dpc-1105	58	18	inhibitor	inhibitor	NOUN
dpc-1105	58	19	.	.	PUNCT
dpc-1105	59	1	rheumatol	rheumatol	VERB
dpc-1105	59	2	ther	ther	ADV
dpc-1105	59	3	.	.	PUNCT
dpc-1105	60	1	2017;4(2):509–513	2017;4(2):509–513	X
dpc-1105	60	2	.	.	PUNCT
dpc-1105	60	3	doi	doi	NOUN
dpc-1105	60	4	:	:	PUNCT
dpc-1105	60	5	10.1007	10.1007	NUM
dpc-1105	60	6	/	/	SYM
dpc-1105	60	7	s40744	s40744	NOUN
dpc-1105	60	8	-	-	PUNCT
dpc-1105	60	9	017	017	NUM
dpc-1105	60	10	-	-	PUNCT
dpc-1105	60	11	0084	0084	NUM
dpc-1105	60	12	-	-	PUNCT
dpc-1105	60	13	0	0	NUM
dpc-1105	60	14	.	.	PUNCT
dpc-1105	61	1	pmid	pmid	NOUN
dpc-1105	61	2	:	:	PUNCT
dpc-1105	61	3	29022197	29022197	NUM
dpc-1105	61	4	.	.	PUNCT
dpc-1105	62	1	references	reference	NOUN
dpc-1105	62	2	1	1	NUM
dpc-1105	62	3	.	.	PUNCT
dpc-1105	62	4	morgado	morgado	PROPN
dpc-1105	62	5	-	-	PUNCT
dpc-1105	62	6	carrasco	carrasco	PROPN
dpc-1105	62	7	d	d	PROPN
dpc-1105	62	8	,	,	PUNCT
dpc-1105	62	9	riera	riera	PROPN
dpc-1105	62	10	-	-	PUNCT
dpc-1105	62	11	monroig	monroig	PROPN
dpc-1105	62	12	j	j	PROPN
dpc-1105	62	13	,	,	PUNCT
dpc-1105	62	14	fustà	fustà	NOUN
dpc-1105	62	15	-	-	PUNCT
dpc-1105	62	16	novell	novell	NOUN
dpc-1105	62	17	x	x	NOUN
dpc-1105	62	18	,	,	PUNCT
dpc-1105	62	19	alsina	alsina	PROPN
dpc-1105	62	20	gibert	gibert	PROPN
dpc-1105	62	21	m.	m.	NOUN
dpc-1105	62	22	response	response	NOUN
dpc-1105	62	23	to	to	PART
dpc-1105	62	24	secukinumab	secukinumab	NOUN
dpc-1105	62	25	after	after	ADP
dpc-1105	62	26	treatment	treatment	NOUN
dpc-1105	62	27	failure	failure	NOUN
dpc-1105	62	28	with	with	ADP
dpc-1105	62	29	ustekinumab	ustekinumab	NOUN
dpc-1105	62	30	in	in	ADP
dpc-1105	62	31	6	6	NUM
dpc-1105	62	32	patients	patient	NOUN
dpc-1105	62	33	with	with	ADP
dpc-1105	62	34	plaque	plaque	NOUN
dpc-1105	62	35	psoriasis	psoriasis	NOUN
dpc-1105	62	36	.	.	PUNCT
dpc-1105	63	1	actas	actas	NOUN
dpc-1105	63	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-1105	63	3	.	.	PUNCT
dpc-1105	64	1	2018;109(6):565	2018;109(6):565	NUM
dpc-1105	64	2	-	-	SYM
dpc-1105	64	3	567	567	NUM
dpc-1105	64	4	.	.	PUNCT
dpc-1105	64	5	doi	doi	NOUN
dpc-1105	64	6	:	:	PUNCT
dpc-1105	64	7	10.1016	10.1016	NUM
dpc-1105	64	8	/	/	SYM
dpc-1105	64	9	j.	j.	PROPN
dpc-1105	64	10	ad.2017.07.019	ad.2017.07.019	PROPN
dpc-1105	64	11	.	.	PUNCT
dpc-1105	65	1	pmid	pmid	NOUN
dpc-1105	65	2	:	:	PUNCT
dpc-1105	65	3	29169562	29169562	NUM
dpc-1105	65	4	.	.	PUNCT
dpc-1105	66	1	2	2	X
dpc-1105	66	2	.	.	X
dpc-1105	66	3	warren	warren	PROPN
dpc-1105	66	4	rb	rb	PROPN
dpc-1105	66	5	,	,	PUNCT
dpc-1105	66	6	barker	barker	PROPN
dpc-1105	66	7	j	j	PROPN
dpc-1105	66	8	,	,	PUNCT
dpc-1105	66	9	burden	burden	NOUN
dpc-1105	66	10	ad	ad	NOUN
dpc-1105	66	11	,	,	PUNCT
dpc-1105	66	12	et	et	PROPN
dpc-1105	66	13	al	al	PROPN
dpc-1105	66	14	.	.	PROPN
dpc-1105	66	15	secukinumab	secukinumab	PROPN
dpc-1105	66	16	has	have	AUX
dpc-1105	66	17	demonstrated	demonstrate	VERB
dpc-1105	66	18	efficacy	efficacy	NOUN
dpc-1105	66	19	and	and	CCONJ
dpc-1105	66	20	safety	safety	NOUN
dpc-1105	66	21	in	in	ADP
dpc-1105	66	22	hard	hard	ADJ
dpc-1105	66	23	-	-	PUNCT
dpc-1105	66	24	to	to	AUX
dpc-1105	66	25	-	-	PUNCT
dpc-1105	66	26	treat	treat	VERB
dpc-1105	66	27	anti	anti	ADJ
dpc-1105	66	28	–	–	NOUN
dpc-1105	66	29	tumor	tumor	ADJ
dpc-1105	66	30	necrosis	necrosis	NOUN
dpc-1105	66	31	factor	factor	NOUN
dpc-1105	66	32	α	α	NOUN
dpc-1105	66	33	failure	failure	NOUN
dpc-1105	66	34	patients	patient	NOUN
dpc-1105	66	35	from	from	ADP
dpc-1105	66	36	the	the	DET
dpc-1105	66	37	united	united	PROPN
dpc-1105	66	38	kingdom	kingdom	PROPN
dpc-1105	66	39	and	and	CCONJ
dpc-1105	66	40	republic	republic	NOUN
dpc-1105	66	41	of	of	ADP
dpc-1105	66	42	ireland	ireland	PROPN
dpc-1105	66	43	:	:	PUNCT
dpc-1105	66	44	results	result	NOUN
dpc-1105	66	45	of	of	ADP
dpc-1105	66	46	the	the	DET
dpc-1105	66	47	signature	signature	NOUN
dpc-1105	66	48	study	study	NOUN
dpc-1105	66	49	.	.	PUNCT
dpc-1105	67	1	j	j	PROPN
dpc-1105	67	2	am	be	AUX